Understanding Your Rights as an Investor in Sage Therapeutics
If you're an investor in Sage Therapeutics, Inc. (NASDAQ: SAGE), it’s crucial to know your rights and stay updated on what’s happening with your investment. Bernstein Liebhard LLP, a respected law firm that focuses on investor rights, is reminding all Sage Therapeutics investors about an important deadline for filing a lead plaintiff motion in a significant securities class action lawsuit.
Details About the Class Action Lawsuit
The lawsuit has been initiated on behalf of all investors who acquired shares of Sage Therapeutics during a specific time frame, which runs from April 12, 2021, to July 23, 2024. If you bought shares during this period, you might be eligible to participate. The complaint claims that there were violations of the Securities Exchange Act of 1934, highlighting potential misrepresentations made by the company regarding its products.
Who Can Join the Lawsuit?
If you purchased shares during the Class Period, it’s worth considering your eligibility to join the lawsuit. Did you own Sage Therapeutics shares? If so, you could play a part in this legal action. Additionally, if you've incurred losses on your investment, it’s important to take steps to protect your rights.
How to File a Lead Plaintiff Motion
Individuals interested in becoming lead plaintiffs must act promptly. The deadline to submit the necessary paperwork is October 28, 2024. By taking this step, you could represent other class members and guide the litigation process. Still, keep in mind that you do not have to be a lead plaintiff to benefit from any potential recovery.
Understanding How Legal Representation Works
Bernstein Liebhard LLP works on a contingency fee basis, which means investors don’t have to worry about paying fees or expenses unless there’s a successful recovery. This setup allows any investor to join the action without the burden of upfront costs, providing a supportive legal partnership throughout the litigation process.
Why This Class Action Matters
This lawsuit is significant because it addresses crucial misrepresentations regarding products linked to brain health from Sage Therapeutics, including zuranolone (SAGE-217/BIIB125), SAGE-718 (dalzanemdor), and SAGE-324 (BIIB124). If the allegations are proven true, they could greatly affect both the value and public perception of the company's stocks.
Proven Success History
Bernstein Liebhard LLP has a notable track record, having secured over $3.5 billion for its clients. Their extensive experience encompasses representing individual investors and large pension funds, showcasing their capability to handle complex securities lawsuits with success.
How to Reach Bernstein Liebhard LLP
If you have any questions about your investments or the lawsuit, feel free to contact Peter Allocco, the Investor Relations Manager at Bernstein Liebhard LLP. This firm is dedicated to helping investors understand their rights and options.
For more information or to discuss your situation with an experienced representative, you can reach Peter at (212) 951-2030 or by email at pallocco@bernlieb.com.
Frequently Asked Questions
What is the deadline for the lead plaintiff motion?
The deadline to file a lead plaintiff motion is October 28, 2024.
Who should file a lead plaintiff motion?
Investors who purchased Sage Therapeutics securities during the Class Period and incurred losses should consider filing.
What does it mean to be a lead plaintiff?
A lead plaintiff represents the interests of all class members and helps direct the litigation.
Is there a cost to participate in the lawsuit?
No, it operates on a contingency fee basis, meaning no fees unless recovery is achieved.
How long has Bernstein Liebhard LLP been in business?
Bernstein Liebhard LLP has been serving investors since 1993, recovering billions for clients.
